Published in AIDS Weekly, April 11th, 2005
According to published research from the United States, "Comparisons of body composition and metabolic changes among antiretroviral-naive patients randomly assigned to didanosine and stavudine- (ddI+d4T) vs. abacavir and lamivudine-(ABC+3TC) containing regimens were assessed in a nested substudy of an ongoing multicenter randomized trial.
"At baseline and every 4 months, body cell mass and total body fat was calculated, anthropometric measurements were performed, and fasting metabolic parameters were obtained."
"The rates of change (unit/month) estimated using...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.